MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash and cash
equivalents
$1,025,987
Accounts receivable, net
$199,954
Prepaid expenses and
other current assets
$128,975
Inventory
$116,217
Intangible assets, gross
$243,644
Deferred offering costs
$1,507,794
Total current assets
$1,471,133
Right-of-use asset, net
$605,289
License agreement, net
$271,143
Intangible assets, net
$202,264
Property and equipment,
net
$56,677
Other assets
$23,057
Less accumulated
amortization
$41,380
Total assets
$4,137,357
Accumulated deficit
-$33,247,219
Total liabilities and
stockholders equity
$4,137,357
Total stockholders
(deficit) equity
-$19,225
Additional paid-in capital
$33,126,398
Common stock, 0.01 par
value 50,000,000...
$54,422
Preferred stock
value-Series BPreferred...
$14,715
Preferred stock
value-Series CPreferred...
$12,040
Preferred stock
value-Series APreferred...
$8,464
Preferred stock
value-Series A1Preferred...
$6,515
Preferred stock
value-Series A2Preferred...
$4,424
Preferred stock
value-Series DPreferred...
$1,016
Total liabilities
$4,156,582
Total current
liabilities
$2,463,141
Total long-term
liabilities
$1,693,441
Accounts payable
$868,545
Accrued liabilities
$785,784
Deferred revenue
$414,871
Operating lease liability
current
$175,948
Derivative liability
$143,382
Convertible note
$74,611
Convertible notes payable,
net
$619,355
Derivative liabilities
long-term
$543,545
Operating lease liability
long term
$488,725
Deferred revenue
long-term
$41,816
Back
Back
Balance Sheet
source: myfinsight.com
20 20 Biolabs, Inc. (AIDX)
20 20 Biolabs, Inc. (AIDX)